Cargando…

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Tadahiro, Takatori, Eriko, Saito, Tatsunori, Omi, Hideo, Kagabu, Masahiro, Miura, Fumiharu, Takeuchi, Satoshi, Sugiyama, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579421/
https://www.ncbi.nlm.nih.gov/pubmed/23263187
http://dx.doi.org/10.1007/s00280-012-2052-2
_version_ 1782260127229804544
author Shoji, Tadahiro
Takatori, Eriko
Saito, Tatsunori
Omi, Hideo
Kagabu, Masahiro
Miura, Fumiharu
Takeuchi, Satoshi
Sugiyama, Toru
author_facet Shoji, Tadahiro
Takatori, Eriko
Saito, Tatsunori
Omi, Hideo
Kagabu, Masahiro
Miura, Fumiharu
Takeuchi, Satoshi
Sugiyama, Toru
author_sort Shoji, Tadahiro
collection PubMed
description PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1–3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: Median age was 50 years (range 32–63 years), with stage Ib2 in 6 cases (26.1 %) and IIb in 17 cases (73.9 %). Complete response was achieved in 5 cases (21.7 %), partial response in 13 (56.5 %), stable disease in 5 (21.7 %); the response rate was 78.3 %, and surgery completion rate was 78.3 %. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2 %) and 21 (91.3 %) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7 %) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95 % Cl, 13.5–38.5 months); median overall survival was 35 months (95 % Cl, 20.9–49.1 months). CONCLUSION: NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events.
format Online
Article
Text
id pubmed-3579421
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-35794212013-02-26 Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix Shoji, Tadahiro Takatori, Eriko Saito, Tatsunori Omi, Hideo Kagabu, Masahiro Miura, Fumiharu Takeuchi, Satoshi Sugiyama, Toru Cancer Chemother Pharmacol Original Article PURPOSE: There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC). METHODS: Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1–3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: Median age was 50 years (range 32–63 years), with stage Ib2 in 6 cases (26.1 %) and IIb in 17 cases (73.9 %). Complete response was achieved in 5 cases (21.7 %), partial response in 13 (56.5 %), stable disease in 5 (21.7 %); the response rate was 78.3 %, and surgery completion rate was 78.3 %. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2 %) and 21 (91.3 %) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7 %) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95 % Cl, 13.5–38.5 months); median overall survival was 35 months (95 % Cl, 20.9–49.1 months). CONCLUSION: NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events. Springer-Verlag 2012-12-23 2013 /pmc/articles/PMC3579421/ /pubmed/23263187 http://dx.doi.org/10.1007/s00280-012-2052-2 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Shoji, Tadahiro
Takatori, Eriko
Saito, Tatsunori
Omi, Hideo
Kagabu, Masahiro
Miura, Fumiharu
Takeuchi, Satoshi
Sugiyama, Toru
Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title_full Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title_fullStr Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title_full_unstemmed Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title_short Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
title_sort neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage ib2 to iib non-squamous cell carcinoma of the uterine cervix
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579421/
https://www.ncbi.nlm.nih.gov/pubmed/23263187
http://dx.doi.org/10.1007/s00280-012-2052-2
work_keys_str_mv AT shojitadahiro neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT takatorieriko neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT saitotatsunori neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT omihideo neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT kagabumasahiro neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT miurafumiharu neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT takeuchisatoshi neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix
AT sugiyamatoru neoadjuvantchemotherapyusingplatinumandtaxanebasedregimensforbulkystageib2toiibnonsquamouscellcarcinomaoftheuterinecervix